HPC
LCTX icon

HM Payson & Co’s Lineage Cell Therapeutics LCTX Stock Holding History

HM Payson & Co’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,650
Closed -$2K – 942
2019
Q4 		$2K Hold
2,650
– – ﹤0.01% 897
2019
Q3 		$3K Hold
2,650
– – ﹤0.01% 900
2019
Q2 		$3K Buy
+2,650
New +$3.05K ﹤0.01% 896

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

HM Payson & Co's LCTX Position: Q1 2020 in Review

HM Payson & Co sold out of Lineage Cell Therapeutics (LCTX) in Q1 2020, closing a stake of 2,650 shares — an estimated $2K sold.

HM Payson & Co first reported a position in LCTX in Q2 2019 and held it in 3 quarters. The position peaked at $3K in Q3 2019. 97 funds tracked by Wall St. Rank hold LCTX as of Q1 2020.

  • HM Payson & Co reported no remaining Lineage Cell Therapeutics position as of Q1 2020 after selling out during the quarter.
  • HM Payson & Co sold 2,650 Lineage Cell Therapeutics shares in Q1 2020, an estimated $2K.
  • HM Payson & Co first reported a position in Lineage Cell Therapeutics in Q2 2019 and held it in 3 quarters.
  • HM Payson & Co's Lineage Cell Therapeutics position peaked at $3K in Q3 2019.
  • 97 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2020.

Based on HM Payson & Co's 13F filing for Q1 2020, filed 1 Jul 2020.